Welch Allyn buy extends Hill-Rom's reach in care continuum
This article was originally published in Clinica
Executive Summary
Hill-Rom is acquiring Welch Allyn for $2.05bn, a move that the Chicago, Illinois group believes will make it a more sought-after partner to improve hospital care and efficiency, as well as expand its reach outside the hospital environment.
You may also be interested in...
Do Hill-Rom, PerkinElmer, Integra Deals Signal 2017 M&A Acceleration?
The second week of 2017 scored a hat trick of M&A deals, including Hill-Rom's $330m acquisition of a privately held diagnostic cardiology and patient-monitoring company. This deal builds on the diagnostics and monitoring product lines Hill-Rom established when it acquired Welch Allyn in 2015.
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.
New’s We’re Watching: J&J's Varipulse PFA Earns CE Mark; Labs Create Intravascular Robots; And More
Medtech Insight's News We're Watching highlights some recent business and R&D developments you may have missed. This week, Biosense Webster’s Varipulse PFA platform earned a CE mark; Biosense Webster also announced the start the pivotal IDE study of its Laminar left atrial appendage elimination system; the FDA approved Boston Scientific's Agent paclitaxel-coated balloon and cleared Medtronic's OsteoCool 2.0 bone ablation system; three papers in Science Robotics describe magnetically controlled vascular robots that could go places wires and catheters cannot.